Institut Curie

Centre National De La Recherche Scientifique

Universitè De Montpellier

Abivax

Université Montpellier 2 Sciences Et Techniques

The University of Montpellier 2 Science and Techniques

Centre National De La Recherche Scientifique-cnrs

Florence Mahuteau-Betzer

Jamal Tazi

David Grierson

Didier Scherrer

Romain Najman

Pierre Roux

Aude Garcel

Noëlie Campos

Julien Santo

Christian Rivalle

Cécile Apolit

Fabrice Lejeune

Julian Venables

Noëlle Campos

A compound: wherein Xrepresents an alkenylene group, a &#x2014;NH&#x2014;CO&#x2014; group, a &#x2014;CO&#x2014;NH&#x2014; group, Yrepresents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, Xrepresents &#x2014;O&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;NH&#x2014;, &#x2014;OCH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or &#x2014;SO&#x2014;NH&#x2014;, and Yrepresents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, optionally substituted by a (C-C)alkyl group, or &#x2014;CRRRor alternatively X&#x2014;Yrepresents &#x2014;CONRR, wherein Rand Rform, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C-C)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

Aryl-n-aryl derivatives for treating a RNA virus infection

A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.

miRNA-124 as a biomarker

Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies

A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I)  means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a &#x2014;CN, hydroxyl, &#x2014;COOR, (C-C)fluoroalkyl, (C-C)fluoroalkoxy, &#x2014;NO, &#x2014;NRR, (C-C)alkoxy, phenoxy and (C-C)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R&#x2032; is a hydrogen atom, halogen atom or group chosen among (C-C)alkyl group, hydroxyl group, &#x2014;COORgroup, &#x2014;NOgroup, &#x2014;NRRgroup, morpholinyl or morpholino group, N-methylpiperazinyl group, (C-C)fluoroalkyl group, (C-C)alkoxy group and &#x2014;CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.

Compounds useful for treating diseases caused by retroviruses

The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.

Use of RBM39 as a biomaker

The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or NR8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or nitrogen atoms; pharmaceutically acceptable salts of said compounds, their isomers and/or a mixture thereof; pharmaceutical composition comprising such a compound; the use of such a compound for preparing a drug intended to treat a genetic disease resulting from at least one mutation causing the occurrence of an early termination codon.

Growing community of inventors

Saint-Remy-les-Chevreuse, France

Florence Mahuteau-Betzer